Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which has completed Phase II clinical trial for the treatment of cyclin-dependent kinase-like 5 deficiency disorder and dravet syndrome. In addition, the company undertakes research programs exploring OV329 in infantile spasm/rare epilepsies; OV882 as a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815, a gene modulation therapy for the treatment of kinesin-family of proteins associated neurological disorder. Ovid Therapeutics Inc. has a collaboration agreement with Takeda Pharmaceutical Company Limited; a license agreement with H. Lundbeck A/S; strategic research collaboration with Columbia University Irving Medical Center; and license agreement with Angelini Pharma to develop and commercialize OV101 for the treatment of angelman syndrome in Europe. The company was incorporated in 2014 and is headquartered in New York, New York.
IPO Year: 2017
Exchange: NASDAQ
Website: ovidrx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/18/2024 | Outperform → Perform | Oppenheimer | |
| 4/30/2024 | $9.00 | Buy | B. Riley Securities |
| 4/29/2024 | $9.00 | Buy | H.C. Wainwright |
| 4/5/2024 | $8.00 | Outperform | Wedbush |
| 12/21/2023 | $11.00 | Buy | BTIG Research |
| 10/13/2023 | $8.00 | Outperform | Oppenheimer |
| 8/25/2021 | $4.50 → $4.00 | Neutral | Citigroup |
Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025Ovid's first program in its KCC2 direct activator library, OV350, has been dosed in a Phase 1 study in Q1 2025; safety and tolerability results expected before year-endCash, cash equivalents and marketable securities of $43.0 million as of March 31, 2025 are expected to support currently planned operations and development programs into the 2H of 2026 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 8:45 AM. ET. A live webcast of the Needham Virtual Healthcare Conference presentation can be accessed through the Events & Presentations section of the company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company's website following the live presentation for approximately 30 da
Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and move its first KCC2 direct activator into the clinicTopline results from Phase 1 study of OV329 expected in Q3 2025, which will include biomarkers that measure clinical effect and target engagement, safety, and tolerabilityOV350, Ovid's first program in its KCC2 direct activator library, initiated a first-in-human study in Q1 2025Cash, cash equivalents and marketable securities of $53.1 million as of December 31, 2024, are expected to support operations and development programs into the second half of
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors. "Stelios is a pioneering force in biotechnology. His vision and strategic acumen have shaped the landscape of our industry—building companies, financing breakthroughs, and enabling transformative medicines. We are honored to welcome him to our Board at a defining moment for Ovid," said Jeremy Levin, D.Phil, MB BChir, Chairman and CEO of Ovid Therapeutics. "With our advancing pipeline, including
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, Massachusetts. A live webcast of the TD Cowen presentation can be accessed through the Events & Presentations section of the company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company's website following the live presentation for approximately 30 days. About
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that management will participate in a virtual presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025, at 4:00 p.m. ET. A live webcast of the presentation can be accessed through the Events & Presentations section of the Company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company's website following the live presentation. About Ovid TherapeuticsOvid Therapeutics Inc. is a
Two preclinical studies to be presented on OV329, a potential next-generation GABA aminotransferase inhibitor, highlighting its safety profile and lack of ocular accumulation relative to vigabatrin Findings to be presented on the effects of OV329 on elevating GABA and suppressing seizures as evaluated in the lithium-pilocarpine model of status epilepticus A study of the effect of OV350, a KCC2 direct activator, in rescuing animals from nerve agent-induced benzodiazepine-resistant refractory status epilepticus to be presented NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions
A Phase 1 SAD/MAD study of OV329 is progressing as planned, and based on encouraging human safety data to date, Ovid will engage regulators about adding cohorts to increase potential dosing opportunities for Phase 2 programs.A regulatory application for a Phase 1 trial of OV350, the first candidate from Ovid's KCC2 direct activator library, is expected to be filed in Q4 2024.The Company will host a KCC2 Download Day on November 13 to provide updates on Ovid's platform of KCC2 direct activators and their broad therapeutic potential.Ovid and Graviton are pausing the initiation of a Phase 2 study of OV888/GV101 to evaluate emerging insights from two recently completed competitor trials in cereb
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced that it will host an investor event focused on its portfolio of direct potassium chloride co-transporter 2 (KCC2) activators on Wednesday, November 13, 2024. The event will take place at Ovid's headquarters in New York's Hudson Yards from 9:30 to 11:30 am ET and will be webcast simultaneously. The session will focus on the biological relevance and broad potential therapeutic opportunity associated with Ovid's KCC2 portfolio. Company management will provide updates on the po
Study found OV329 cleared and remained undetectable in the retina, eye, and brain tissues of mice, unlike vigabatrin which has repeatedly shown to preferentially accumulate in mouse retinas, eyes, and other tissues OV329's potency, mechanism of inhibition, short half-life, rapid tissue elimination and prolonged pharmacodynamic effect suggests it delivers a differentiated ocular safety and efficacy profile from vigabatrin A Phase 1 trial evaluating OV329 in healthy volunteers is on-track for completion in late 2024 and will evaluate safety and two biomarkers for target engagement and evidence of clinical effect NEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:O
Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti
SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)
SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)
SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)
SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)
SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)
SC 13G - Ovid Therapeutics Inc. (0001636651) (Subject)
SC 13G - Ovid Therapeutics Inc. (0001636651) (Subject)
SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)
SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)
SC 13G - Ovid Therapeutics Inc. (0001636651) (Subject)
DEFA14A - Ovid Therapeutics Inc. (0001636651) (Filer)
DEF 14A - Ovid Therapeutics Inc. (0001636651) (Filer)
10-Q - Ovid Therapeutics Inc. (0001636651) (Filer)
8-K - Ovid Therapeutics Inc. (0001636651) (Filer)
8-K - Ovid Therapeutics Inc. (0001636651) (Filer)
PRE 14A - Ovid Therapeutics Inc. (0001636651) (Filer)
10-K/A - Ovid Therapeutics Inc. (0001636651) (Filer)
10-K - Ovid Therapeutics Inc. (0001636651) (Filer)
8-K - Ovid Therapeutics Inc. (0001636651) (Filer)
8-K - Ovid Therapeutics Inc. (0001636651) (Filer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
3 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors. "Stelios is a pioneering force in biotechnology. His vision and strategic acumen have shaped the landscape of our industry—building companies, financing breakthroughs, and enabling transformative medicines. We are honored to welcome him to our Board at a defining moment for Ovid," said Jeremy Levin, D.Phil, MB BChir, Chairman and CEO of Ovid Therapeutics. "With our advancing pipeline, including
NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced the appointment of Amanda Banks, M.D., as Chief Development Officer. Dr. Banks will oversee Ovid's clinical development, medical, and regulatory affairs functions as well as drive corporate development strategy and execution in partnership with the Company's leadership team. Dr. Banks brings to Ovid broad and deep experience in neurology, clinical strategy, and business development. Her strategic acumen will serve Ovid at an important juncture for the Company as it determ
Neurologists/epileptologists Dr. Imad Najm of the Cleveland Clinic Neurological Institute and the Cleveland Clinic Epilepsy Center, and Dr. Raman Sankar, the Emeritus Chief of Pediatric Neurology at UCLA Health, appointed to Ovid's Scientific Advisory Board (SAB)Neuroscientists Dr. Jamie Maguire of Tufts University and Dr. Jeff Noebels of Baylor College of Medicine, appointed to the SAB to contribute expertise in neurophysiology, hyperexcitability and network effectsThe SAB will advise on the potential application of Ovid's compounds to broader disorders in which they may offer therapeutic promise, including brain conditions caused by hyperexcitability, neurovascular and neuro-inflammatory d
Dr. Zhong Zhong joins Ovid as Chief Scientific Officer (CSO) and Dr. Manoj Malhotra assumes role as Chief Medical Officer (CMO) following the planned retirement of Dr. Claude NicaiseMeg Alexander promoted to Chief Strategy OfficerOvid streamlined G&A infrastructure to improve operational efficiency and reduce costs NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today announced leadership appointments intended to enhance the execution of its corporate strategy and the scientific stewardship of its therapeutic
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Kevin Fitzgerald, Ph.D., to its Board of Directors. "We are very pleased to have Kevin join our Board of Directors. His experience transforming state-of-the-art science and novel platform technologies into commercial medicines will provide valuable perspective for Ovid's neuroscience development programs," said Jeremy Levin, D.Phil, MB BChir, Chairman and Chief Executive Officer of Ovid Therapeutics. "Kevin's expertise across small molecule an
New appointments strengthen neuroscience-focused Scientific Advisory Board NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the appointment of Joy A. Cavagnaro, Ph.D., and Bruce A. Sullenger, Ph.D. to its Scientific Advisory Board. "Ovid is building the intellectual and scientific platform to tackle the big questions in neuroscience so as to develop new medicines. To that end, Ovid is deepening the expertise and strengths of our Scientific Advisory Board by the addition of key leaders in specific areas. According
Closed royalty, license and termination agreement with Takeda for soticlestat; Ovid Therapeutics received an upfront payment of $196.0 million and is eligible to receive up to $660.0 million in additional milestone payments, plus tiered double-digit royalties, up to 20%, on sales if soticlestat is commercializedEnding Q1'21 cash and cash equivalents balance of $233.1 million and reduced cash burn supports prioritization of resources to advance robust early-stage neuroscience pipeline and explore full ecosystem of complementary external innovation Company is actively pursuing business development opportunities to advance its early-stage neuroscience pipeline and is planning to evaluate clinic
NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Professor Robert S. Langer, Sc.D., as Chairman of its Scientific Advisory Board. "We welcome Professor Robert Langer, who has joined Ovid as the new Chair of our Scientific Advisory Board," said Amit Rakhit, M.D., MBA, President, Ovid Therapeutics. "Bob will help guide Ovid's strategy to tackle opportunities and scientific questions underlying disorders in the brain. His perspective will be invaluable as we advance our pipeline of next-genera
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
Oppenheimer downgraded Ovid Therapeutics from Outperform to Perform
B. Riley Securities initiated coverage of Ovid Therapeutics with a rating of Buy and set a new price target of $9.00
H.C. Wainwright initiated coverage of Ovid Therapeutics with a rating of Buy and set a new price target of $9.00
Wedbush initiated coverage of Ovid Therapeutics with a rating of Outperform and set a new price target of $8.00
BTIG Research initiated coverage of Ovid Therapeutics with a rating of Buy and set a new price target of $11.00
Oppenheimer initiated coverage of Ovid Therapeutics with a rating of Outperform and set a new price target of $8.00
Citigroup reiterated coverage of Ovid Therapeutics with a rating of Neutral and set a new price target of $4.00 from $4.50 previously
Cantor Fitzgerald downgraded Ovid Therapeutics from Buy to Neutral and set a new price target of $4.00
UBS Group reiterated coverage of Ovid Therapeutics with a rating of Neutral and set a new price target of $5.00 from $4.00 previously
RBC Capital Mkts downgraded Ovid Therapeutics from Outperform to Sector Perform and set a new price target of $5.00